Literature DB >> 6463452

Survivorship analysis when cure is a possibility: a Monte Carlo study.

A I Goldman.   

Abstract

Parametric survivorship analyses of clinical trials commonly involves the assumption of a hazard function constant with time. When the empirical curve obviously levels off, one can modify the hazard function model by use of a Gompertz or Weibull distribution with hazard decreasing over time. Some cancer treatments are thought to cure some patients within a short time of initiation. Then, instead of all patients having the same hazard, decreasing over time, a biologically more appropriate model assumes that an unknown proportion (1 - pi) have constant high risk whereas the remaining proportion (pi) have essentially no risk. This paper discusses the maximum likelihood estimation of pi and the power curves of the likelihood ratio test. Monte Carlo studies provide results for a variety of simulated trials; empirical data illustrate the methods.

Entities:  

Mesh:

Year:  1984        PMID: 6463452     DOI: 10.1002/sim.4780030208

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Flexible Cure Rate Modeling Under Latent Activation Schemes.

Authors:  Freda Cooner; Sudipto Banerjee; Bradley P Carlin; Debajyoti Sinha
Journal:  J Am Stat Assoc       Date:  2007-06-01       Impact factor: 5.033

2.  Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models.

Authors:  A D Tsodikov; J G Ibrahim; A Y Yakovlev
Journal:  J Am Stat Assoc       Date:  2003-12-01       Impact factor: 5.033

3.  Modelling geographically referenced survival data with a cure fraction.

Authors:  Freda Cooner; Sudipto Banerjee; A Marshall McBean
Journal:  Stat Methods Med Res       Date:  2006-08       Impact factor: 3.021

4.  The large sample distribution of the weighted log rank statistic under general local alternatives.

Authors:  M Ewell; J G Ibrahim
Journal:  Lifetime Data Anal       Date:  1997       Impact factor: 1.588

5.  Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Authors:  Sanjiv S Agarwala; Sandra J Lee; Waiki Yip; Uma N Rao; Ahmad A Tarhini; Gary I Cohen; Douglas S Reintgen; Terry L Evans; Joanna M Brell; Mark R Albertini; Michael B Atkins; Shaker R Dakhil; Robert M Conry; Jeffrey A Sosman; Lawrence E Flaherty; Vernon K Sondak; William E Carson; Michael G Smylie; Alberto S Pappo; Richard F Kefford; John M Kirkwood
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

6.  Utilization of a Mixture Cure Rate Model based on the Generalized Modified Weibull Distribution for the Analysis of Leukemia Patients.

Authors:  Mohamed Elamin Omer; Mohd Abu Bakar; Mohd Adam; Mohd Mustafa
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

7.  Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD.

Authors:  William Knebel; Jim Rogers; Dan Polhamus; James Ermer; Marc R Gastonguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-11-06       Impact factor: 2.745

8.  Estimating the turning point of the log-logistic hazard function in the presence of long-term survivors with an application for uterine cervical cancer data.

Authors:  Patrick Borges
Journal:  J Appl Stat       Date:  2020-02-03       Impact factor: 1.416

9.  A cure-rate model for Q-learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients.

Authors:  Erica E M Moodie; David A Stephens; Shomoita Alam; Mei-Jie Zhang; Brent Logan; Mukta Arora; Stephen Spellman; Elizabeth F Krakow
Journal:  Biom J       Date:  2018-05-16       Impact factor: 2.207

10.  A multivariate cure model for left-censored and right-censored data with application to colorectal cancer screening patterns.

Authors:  Yolanda C Hagar; Danielle J Harvey; Laurel A Beckett
Journal:  Stat Med       Date:  2016-03-18       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.